- Catalent ( NYSE: CTLT ) has signed a commercial supply agreement with Sarepta Therapeutics ( NASDAQ: SRPT ) to make SRPT's muscle wasting gene therapy candidate.
- As per the deal, CTLT will make SRP-9001 for the treatment of Duchenne muscular dystrophy (DMD).
- "The agreement also structures how Catalent may support multiple gene therapy candidates in Sarepta’s pipeline for limb-girdle muscular dystrophy (LGMD)," CTLT said in a statement on Thursday.
- CTLT had already been working with SRPT in a partnership that spanned nearly a decade across multiple programs.
- Catalent ( CTLT ) stock closed 2.2% higher at $46.45 on Wednesday, while Sarepta ( SRPT ) ended +0.1% at $124.98.
For further details see:
Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal